skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Akt inhibitor AZD5363 (Code C102564)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Akt inhibitor AZD5363

Definition: A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.

Display Name: Akt inhibitor AZD5363

Label: Akt inhibitor AZD5363

NCI Thesaurus Code: C102564 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3502775  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Akt inhibitor AZD5363

External Source Codes: 
PDQ Closed Trial Search ID 688304
PDQ Open Trial Search ID 688304 (check for NCI PDQ open clinical trial info)
UMLS CUI C3502775

Other Properties:
     Name Value (qualifiers indented underneath)
code C102564
Contributing_Source CTRP
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom